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Ataxia pancytopenia syndrome (ATXPC; MIM 159550) is an autosomal dominant cerebellar
ataxia associated with hematological abnormalities including pancytopenia and a predisposition
to haematological malignancy (myelodysplasia and acute myeloid leukaemia). To date, 4
families have been described harboring gain of function SAMD9L mutations which underlie
ATXPC.1–4 Here we describe a de novo SAMD9L pathogenic variant in a patient with mye-
lodysplasia, presenting with a subacute cerebellar syndrome.
Case Presentation
A 28-year-old woman presented to a tertiary neurologic center with a 6-week history of
headache, diplopia, and ataxia, which started after cellulitis at the site of a pneumococcal and
influenza vaccination. On examination, there was mild gait ataxia, slow saccades, diplopia in all
directions of gaze without extraocular nerve palsy, and prominent downbeating nystagmus. Her
medical history confirmed myelodysplastic syndrome, diagnosed 12 years previously. There
was no relevant family history.
Initial investigations, including CSF and a broad panel of autoimmune and metabolic in-
vestigations, were unremarkable. MRI of the brain demonstrated confluent, symmetrical
periventricular and deep white matter T2 hyperintensity, extending to involve the striatum,
with periventricular cystic foci surrounding the lateral ventricles (figure 1A). There was
marked cerebellar atrophy with both vermian and hemispheric volume loss (figure 1B).
Whole body [18F]FDG-PET demonstrated diffuse cerebellar hypometabolism (figure 1C)
and excluded active malignancy. Electroencephalography revealed occasional sharpened
theta waves over the frontal region against a posterior background activity in the alpha range.
Ophthalmology examination demonstrated no ocular abnormality with normal optical co-
herence tomography.
Whole genome sequencing of the proband and both parents revealed a heterozygous missense
pathogenic variant of the SAMD9L gene (NM_152703.5:c.2956C>T, p.(Arg986Cys)) in the
proband only and confirmed parentage. Sanger sequencing was carried out in the proband and
both parents, confirming that the variant had arisen de novo in the patient (figure 1D). This
variant is not seen in the gnomAD population database but was previously described by Tesi
et al.1 in a 3-generation family with ATXPC (F1).
Array comparative genomic hybridization (CGH) demonstrated a mosaic interstitial deletion
on the long arm of chromosome 7 within the hematopoietic cell line, from bands q11.23 to q33
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(arr[GRCh37] 7q11.23q33 (76030573_137802149)x1[0.5],
figure e-1, links.lww.com/NXG/A404). This deletion en-
compasses the SAMD9L gene and was present in 50% of cells.
Discussion
ATXPC is caused by gain of function pathogenic variants of
the SAMD9L tumor suppressor gene. The disorder is ex-
tremely rare; of those 35 patients with SAMD9L mutations
reported worldwide by the Human Gene Mutation Database,
6 have ATXPC, whereas the remainder are characterized by
myelodysplastic syndrome or bone marrow failure.2 The lit-
erature reports 4 families in addition to the case reported
here.1,3,4
Overactivity of SAMD9L results in the cerebellar atrophy and
pancytopenia that engender the clinical presentation. Brain
MRI demonstrates cerebellar volume loss accompanied fre-
quently by periventricular white matter T2 hyperintensities.1,4,5
Histopathologic studies have shown diffuse loss of Purkinje
cells and—to a lesser extent—cerebellar granule cells, the
mechanism for which remains unclear.4
Germline SAMD9L gain of function pathogenic variants
cause bone marrow suppression with pancytopenia. Acquired
monosomy 7 or partial deletion of chromosome 7may arise to
circumvent the repression of hematopoiesis. These can act as
a “rescue mechanism” that inactivates the gain of function
mutation by nonrandom loss of the mutated SAMD9L allele
(figure e-2, links.lww.com/NXG/A405).6 Consequently,
spontaneous recovery from the pancytopenia may occur
(“hemopoietic reversion”). However, partial or total deletions
of chromosome 7 may lead to clonal expansion of a cell line
(myelodysplastic syndrome), as occurred in our patient, and
predispose to acute myeloid leukaemia.7
The age at onset of neurologic symptoms in familial cases varies
widely, ranging from 4 to 62 years, followed by invariably slow
progression.4,5 The neurologic presentation is often preceded by
the hematological manifestations, as in the patient reported here.
Figure 1 Neuroimaging and Genetic Abnormalities
Brain MRI changes included periventricular T2 white matter
hyperintensities with cystic change (arrow) (A), alongside
marked cerebellar atrophy with both vermian and hemi-
spheric volume loss (B). [18F]FDG-PET revealed diffuse cer-
ebellar hypometabolism (C). Whole genome sequencing
demonstrated a de novo gain of function (GOF) mutation in
the SAMD9L gene on chromosome 7, confirmed by sanger
sequencing of the proband and asymptomatic parents (D).
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Although the exact triggers for this patient’s subacute presentation
are not clear, possibilities include decompensation of the already
compromised cerebellar system because of intercurrent infection
or parainfectious phenomenon after recent immunization.
The mainstay of the management for SAMD9L-associated
hematological abnormalities includes monitoring for the de-
velopment of hematological malignancy and allogenic stem
cell transplantation. Stem cell transplantation seems to have
no effect on neurologic outcomes, and the management of
neurologic abnormalities of ATXPC remains supportive.1
With input from the wider multidisciplinary team, in-
cluding neuro-ophthalmology, hematology, clinical ge-
netics, and physiotherapy, the patient reported here
continues to be independent and an avid cyclist. The pa-
tient initially found improvement in her diplopia with the
use of occlusive lenses; however, these are no longer re-
quired, and the only remaining abnormality on examina-
tion is mild nystagmus.
Shortly after diagnosis, the patient became pregnant. Prenatal
testing, by chorionic villus sampling at 12 weeks, confirmed
the baby to be negative for the familial variant in SAMD9L
(unaffected). The patient remained well throughout an un-
eventful pregnancy.
This case of de novo SAMD9L pathogenic variant in ATXPC
highlights the value of whole genome sequencing, leading to
an accurate diagnosis, appropriate surveillance and treatment,
and opening the option of prenatal diagnosis.
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